Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14430894 | 0.95 | MAPT (0.43) | MAPTHCAR2ALOX15 | |
| SCHEMBL5468306 | 0.95 | MAPT (0.43) | MAPTHCAR2ALOX15 | |
| SCHEMBL5460105 | 0.77 | MAPT (0.40) | TLR8MAPTALOX15 | |
| SCHEMBL14430913 | 0.76 | MAPT (0.47) | TLR8MAPTALOX15 | |
| SCHEMBL5465806 | 0.74 | MAPT (0.35) | TLR8MAPT | |
| SCHEMBL14430889 | 0.74 | MAPT (0.45) | MAPTALOX15 | |
| SCHEMBL14430887 | 0.74 | MAPT (0.45) | MAPTALOX15 | |
| SCHEMBL5470194 | 0.74 | MAPT (0.45) | MAPTALOX15 | |
| SCHEMBL4496845 | 0.73 | MAPT (0.41) | TLR8MAPT | |
| SCHEMBL5457375 | 0.71 | MAPT (0.42) | MAPTALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191373-A1 | Heterocyclic compounds for use in the treatment of viral infections | REGAN FOUNDATION (BE) | 2007-08-16 | — | — | US | claimed |
| US-20070191373-A1 | Heterocyclic compounds for use in the treatment of viral infections | REGAN FOUNDATION (BE) | 2007-08-16 | — | — | US | disclosed |
| US-20070191373-A1 | Heterocyclic compounds for use in the treatment of viral infections | REGAN FOUNDATION (BE) | 2007-08-16 | — | — | US | disclosed |
| US-20070191373-A1 | Heterocyclic compounds for use in the treatment of viral infections | REGAN FOUNDATION (BE) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191373-A1 | Heterocyclic compounds for use in the treatment of viral infections | TPMT, TYMP, HAVCR2 | TLR8 108/4885MAPT 3202/4885HCAR2 1237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.